A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
To determine the efficacy of MMB versus DAN assessed by improvement in Myelofibrosis Symptom Assessment Form subjects with Primary Myelofibrosis, post-Polycythemia Vera myelofibrosis , or Post Essential Thrombocythemia Myelofibrosis who were previously treated with approved JAK inhibitor therapy.
This Study is
No Longer Enrolling
Adult
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Treatment
University of Colorado Hospital
Protocol Number: 19-2520
More information available at ClinicalTrials.gov: NCT04173494
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers